biotech · Low Grade Upper Tract Urothelial Cancer
Steba Biotech
STEBA Biotech S.A
STEBA Biotech is a biotech organization headquartered in EU. Primary therapeutic focus areas include Low Grade Upper Tract Urothelial Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent re
Toussus-le-Noble, FR HQ
21 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Toussus-le-Noble, FR
- Employees
- 21
- Programs
- 1
- Drugs
- 4
- Patents
- 0
CLIN2001UCM301
Phase 3 · small molecule · Low Grade Upper Tract Urothelial Cancer
CLIN2001UCM301 for Low Grade Upper Tract Urothelial Cancer is a Phase 3 program (small_molecule) at STEBA Biotech S.A with 1 ClinicalTrials.gov record(s).
Internal code CLIN2001UCM301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- STEBA Biotech S.A
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Low Grade Upper Tract Urothelial Cancer
- Status
- active
- Trials
- 1